Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 6,631

Document Document Title
WO/2012/142960A1
Disclosed is an anti-infective drug―macrolide compound, preparation and uses thereof. Macrolide compound, namely erythromycin ethylsuccinate crystalline hydrate, which has less moisture absorption and good storage stability, can be use...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/129473A1
The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitabl...  
WO/2012/127351A1
A process for the preparation of compound of Formula (I) is provided. Formula - I  
WO/2012/127410A1
A method for the synthesis of a compound of formula (1) or a salt thereof, wherein A is a carbohydrate linker which is a lactosyl moiety or which consists of a lactosyl moiety and at least one monosaccharide unit selected from the group ...  
WO/2012/121297A1
[Problem] To provide a method for producing an ascorbic acid 2-glucoside anhydrous crystal-containing powder with which it is possible to produce a powder that will not show significant solidification, even when the percentage of ascorbi...  
WO/2012/118048A1
A novel monoalkylamino intermediate (I); and a process of producing a compound represented by formula (III), which is an antibacterial agent for animals, through the novel monoalkylamino intermediate.  
WO/2012/115256A1
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).  
WO/2012/116196A2
The invention provides methods for producing compounds comprising a substitution at the 1'-position of a lactosyl ring. Also provided are compounds having a radionuclide, such as 18F substituted at the 1'-position of a lactosyl ring. Com...  
WO/2012/051126A3
The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.  
WO/2012/105562A1
The inventors have successfully obtained a compound having josamycin as the lead mother nucleus and having excellent antibacterial activity against the causative bacteria of respiratory tract infection in animals.  
WO/2012/105563A1
It was found compound (1) has excellent antibacterial activity against the causative bacteria of respiratory tract infection in animals.  
WO/2010/015703A3
The invention relates to novel anti-bacterial 15-membered 6-O-substituted-8a-aza-8a- homoerythromycin A and 6-O-substituted-9a-aza-9a-homoerythromycin A, their 6-O- substituted-3-O-decladinosyl-3-oxy and 6-O-substituted-3-O-decladinosyl-...  
WO/2012/076989A1
The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositio...  
WO/2012/070024A1
Compositions for the treatment of cancer comprising coumarin and thiocoumarin derivatives of Formulas I- XII are disclosed. Said derivatives preferentially inhibit carbonic anhydrase IX and XII (which are associated with hypoxic and meta...  
WO/2012/065054A1
A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula I: A-B wherein A comprises a carbohydrate that is a neuraminidase or galactosidase substrate; B comprises an odorant moiety; B is co...  
WO/2012/061984A1
The present invention discloses a method for preparing high purity paeoniflorin and albiflorin simultaneously comprising: extraction the raw material peony by percolation or heating reflux to obtain the peony extract solution, then purif...  
WO/2012/061931A1
The present invention relates to the use of a natural compound in diabetes prevention. More specifically, the invention relates to the use of geniposide as a pancreatic beta cell protectant for diabetes prevention and treatment.  
WO/2012/061477A1
The invention provides coelenterazine derivatives which are substrates for a non-luminescent enzyme and a pro-substrate for a luminescent enzyme. The invention also provides a method of using the derivatives.  
WO/2012/051126A2
The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.  
WO/2012/048522A1
A new fructosylated puerarin represented by Formula (I), a preparation method therefor and a use thereof in preparation of drugs for treating cardio-cerebrovascular diseases and/or tumor related diseases. R1 and R2 in Formula (I) are eac...  
WO/2012/049521A1
There is provided a method of glycosylating an aminocoumarin compound comprising conjugating a sugar to the 4'-OH position of the core of the aminocoumarin compound. Also provided is an aminocoumarin compound glycosylated at the 4'-OH po...  
WO/2012/047763A2
Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.  
WO/2012/038614A1
The present invention relates to sulfonated coumarins, to the synthesis thereof, to fluorogenic substrates resulting from grafting said coumarins onto sugars, to a method for preparing said substrates, and to the uses thereof. The substi...  
WO/2012/038372A1
The present invention concerns a process for the preparation of the compound of formula (1). The compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin...  
WO/2012/033218A1
The objective of the present invention is to provide novel 2-O-α-D-glucosyl-L-ascorbic acid crystals, a method for producing the novel 2-O-α-D-glucosyl-L-ascorbic acid crystals, and use of the novel 2-O-α-D-glucosyl-L-ascorbic acid cr...  
WO/2011/150775A1
Disclosed is a method for treating a fermentation liquor of natamycin which is a fungus inhibitor. In this method, protease and lipase are added to the fermentation liquor for enzymolysis. Water insoluble proteins and lipid in filter cak...  
WO/2011/147316A1
Disclosed are levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains certain content of isobutyrylspiramycin II...  
WO/2011/147313A1
Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the...  
WO/2011/137758A1
Provided are ketolide derivatives of general formula (I) or (II), or pharmaceutically acceptable salts or esters thereof formed with inorganic acids or organic acids. In the formula, Ar represents aromatic heterocyclic alkyl or substitut...  
WO/2011/131749A1
(E)-11,12-Didehydro-11,12-dideoxy 14-membered macrolides and 15-membered azalide macrolides represented by Formula (I): useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil domi...  
WO/2011/127948A1
Analogues of etoposide for the treatment of patients having a tumour, more particularly a tumour that is metastatic and/or that reduces an organ function, are provided. The invention also relates to an in vitro method of selecting a resp...  
WO/2011/128869A1
This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6- [(2S, 3R, 4S, 6R)-4-dimethylamino-3- hydroxy-6-methyloxan-2-yl]oxy-14- ethyl-7, 12, 13-tri...  
WO/2011/128115A1
Analogues of etoposide for the treatment of patients having a tumour, more particularly a tumour that is metastatic and/or that reduces an organ function, are provided. The invention also relates to an in vitro method of selecting a resp...  
WO/2011/119604A1
New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.  
WO/2011/119549A1
The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes...  
WO/2011/054837A3
The present invention relates to novel compounds, more precisely to novel bifunctional prodrugs and drugs. In a further aspect, the invention relates to pharmaceutical compositions comprising said prodrugs and drugs, and to the use there...  
WO/2011/110084A1
Method for preparing isovalerylspiramycin I, II or III and pharmaceutical composition containing the compound thereof which has antibacterial activity are provided. Isovalerylspiramycin I, II or III is obtained by the procedures of prima...  
WO/2010/092592A3
The process of preparation of pure diosmin that is independent of hesperidine used for conversion is described. Process is effective in controlling the impurity by crystallization. The cost effective and ecofriendly process enables recov...  
WO/2011/107494A1
The invention relates to aromatic glycoside derivatives of the formula (I), in which the groups have the given meanings, to the physiologically acceptable salts thereof, and to methods for the production thereof. The compounds are suitab...  
WO/2011/099570A1
Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or...  
WO/2011/097950A1
Compounds represented by general formula (I) or their pharmaceutically acceptable salts or esters with mineral or organic acids are disclosed. Wherein Ar is aromatic heterocyclic alkyl or substituted aromatic heterocyclic alkyl, and X is...  
WO/2010/067008A3
The invention relates to compounds having formula (I) wherein: R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 represents a hydroxyl group, a thiol group, a (C1-C4)alkyloxy group or a thio(C1-C4)alkyl group; and n is an integer...  
WO/2010/067007A3
The invention relates to a method for preparing morphine-6-glucuronide or one of the derivatives thereof, comprising the following steps: (i) reacting a compound having formula (I), wherein R1 represents a carbonyl group, COR5CO or S02R6...  
WO/2010/067010A3
The invention relates to derivatives of morphine-6-glucuronide having formula (I) wherein R1 is a 5-membered heteroaromatic group optionally substituted by one or more substituents selected from among halogen atoms and (C1-C4)alkyl, halo...  
WO/2011/048148A3
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/073926A1
The invention relates to an amorphous non-crystalline glass form (Form-ll) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4- dimethylamino-3- hydroxy-6-methyloxan-2-yl]oxy-14- ethyl-7, 12, 13- trihydroxy-4-[(2R, 4R, 5S...  
WO/2011/073927A1
The invention relates to an amorphous non-crystalline glass form (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R) -2-ethyl-3,4, 10- trihydroxy- 3,5,6,8,10,12,14- heptamethyl-15-oxo- 11- {[3,4,6- trideoxy-3- (dimethylamino) -β-D-xylo- hexopyranosyl]...  
WO/2011/061747A1
This invention relates to conjugates of polysaccharides and active drug components and uses thereof in a variety of therapies, such as antifungal and antileishmanial therapies.  
WO/2011/054837A2
The present invention relates to novel compounds, more precisely to novel bifunctional prodrugs and drugs. In a further aspect, the invention relates to pharmaceutical compositions comprising said prodrugs and drugs, and to the use there...  

Matches 301 - 350 out of 6,631